JP7247113B2 - ミクログリアの活性化を抑制する方法 - Google Patents

ミクログリアの活性化を抑制する方法 Download PDF

Info

Publication number
JP7247113B2
JP7247113B2 JP2019567345A JP2019567345A JP7247113B2 JP 7247113 B2 JP7247113 B2 JP 7247113B2 JP 2019567345 A JP2019567345 A JP 2019567345A JP 2019567345 A JP2019567345 A JP 2019567345A JP 7247113 B2 JP7247113 B2 JP 7247113B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522535A (ja
JP2020522535A5 (enExample
Inventor
ブートフスキー，オレグ
ウェイナー，ハワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of JP2020522535A publication Critical patent/JP2020522535A/ja
Publication of JP2020522535A5 publication Critical patent/JP2020522535A5/ja
Priority to JP2023041296A priority Critical patent/JP7777096B2/ja
Application granted granted Critical
Publication of JP7247113B2 publication Critical patent/JP7247113B2/ja
Priority to JP2024231213A priority patent/JP2025066722A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019567345A 2017-06-06 2018-06-06 ミクログリアの活性化を抑制する方法 Active JP7247113B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023041296A JP7777096B2 (ja) 2017-06-06 2023-03-15 ミクログリアの活性化を抑制する方法
JP2024231213A JP2025066722A (ja) 2017-06-06 2024-12-26 ミクログリアの活性化を抑制する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515711P 2017-06-06 2017-06-06
US62/515,711 2017-06-06
PCT/US2018/036261 WO2018226833A1 (en) 2017-06-06 2018-06-06 Methods of suppressing microglial activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023041296A Division JP7777096B2 (ja) 2017-06-06 2023-03-15 ミクログリアの活性化を抑制する方法

Publications (3)

Publication Number Publication Date
JP2020522535A JP2020522535A (ja) 2020-07-30
JP2020522535A5 JP2020522535A5 (enExample) 2021-05-27
JP7247113B2 true JP7247113B2 (ja) 2023-03-28

Family

ID=64566373

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019567345A Active JP7247113B2 (ja) 2017-06-06 2018-06-06 ミクログリアの活性化を抑制する方法
JP2023041296A Active JP7777096B2 (ja) 2017-06-06 2023-03-15 ミクログリアの活性化を抑制する方法
JP2024231213A Pending JP2025066722A (ja) 2017-06-06 2024-12-26 ミクログリアの活性化を抑制する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023041296A Active JP7777096B2 (ja) 2017-06-06 2023-03-15 ミクログリアの活性化を抑制する方法
JP2024231213A Pending JP2025066722A (ja) 2017-06-06 2024-12-26 ミクログリアの活性化を抑制する方法

Country Status (5)

Country Link
US (2) US20200165338A1 (enExample)
EP (1) EP3634478A4 (enExample)
JP (3) JP7247113B2 (enExample)
CA (1) CA3066353A1 (enExample)
WO (1) WO2018226833A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125939A4 (en) * 2020-03-25 2024-04-24 The Brigham & Women's Hospital, Inc. Inhaled xenon therapy in neurodegenerative disease
WO2021231566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
WO2021255189A1 (en) * 2020-06-17 2021-12-23 Tiziana Life Sciences, Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
US20230227555A1 (en) * 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
EP4355342A4 (en) * 2021-06-17 2025-04-23 Spinalcyte, LLC Fibroblast based therapeutics of amyotrophic lateral sclerosis
CA3234994A1 (en) * 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503449A (ja) 2004-06-03 2008-02-07 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
AU2006291005A1 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503449A (ja) 2004-06-03 2008-02-07 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Brain Behav. Immun., 2015, Vol.55, pp.236-248
BRAIN, 2016, Vol.139, pp.1939-1957
Molecular and Cellular Neuroscience, 2015, Vol.66, pp.91-98
Swiss. Med. Wkly., 2012, Vol.142, #w13711
Treatment of Alzheimer's disease by modulation of microglialneuroinflammation by nasal anti-CD3mAb，Alzheimer's Association International Conference Meeting Abstract, 2022, [retrieved on 2022_10_28]，<https://alz.confex.com/alz/2022/meetingapp.cgi/Paper/68761>

Also Published As

Publication number Publication date
JP7777096B2 (ja) 2025-11-27
WO2018226833A1 (en) 2018-12-13
US20230039028A1 (en) 2023-02-09
JP2025066722A (ja) 2025-04-23
JP2020522535A (ja) 2020-07-30
JP2023085336A (ja) 2023-06-20
CA3066353A1 (en) 2018-12-13
US20200165338A1 (en) 2020-05-28
EP3634478A4 (en) 2021-03-24
EP3634478A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
JP7777096B2 (ja) ミクログリアの活性化を抑制する方法
JP5027512B2 (ja) 免疫調節法
JP2004536072A (ja) 種々の疾患の治療のための抗−ｎｇｆ抗体
JP2011006464A (ja) 喘息の治療における抗−ＴＮＦα抗体
CN111511390B (zh) 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
JP2013193995A (ja) 特発性炎症性筋疾患の予防又は治療剤
TW202434633A (zh) 治療甲狀腺眼疾之方法
JP2020522535A5 (enExample)
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
JP7789368B2 (ja) 炎症性腸疾患に対する治療用抗体
CA3130348A1 (en) A method for immunosuppression
JP2021155343A (ja) 肺高血圧症の予防又は治療薬
HK1098085B (en) Methods of modulating immunity
CN108473576A (zh) 用于治疗复发形式的多发性硬化的方法
NZ619873B2 (en) Methods and compositions for treating asthma using anti-il-13 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230315

R150 Certificate of patent or registration of utility model

Ref document number: 7247113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250